Revolve Wealth Partners LLC Acquires 4,737 Shares of Abbott Laboratories $ABT

Revolve Wealth Partners LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 124.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,539 shares of the healthcare product maker’s stock after purchasing an additional 4,737 shares during the period. Revolve Wealth Partners LLC’s holdings in Abbott Laboratories were worth $775,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Freemont Management S.A. lifted its position in shares of Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after acquiring an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories during the fourth quarter worth about $116,580,000. Thrivent Financial for Lutherans raised its stake in Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares during the period. Aureus Asset Management LLC lifted its holdings in Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after purchasing an additional 66,422 shares in the last quarter. Finally, Concurrent Investment Advisors LLC boosted its stake in Abbott Laboratories by 23.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 88,784 shares of the healthcare product maker’s stock worth $11,124,000 after purchasing an additional 17,137 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ABT. Bank of America reduced their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Stifel Nicolaus dropped their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. UBS Group reduced their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Citigroup boosted their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Finally, Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a report on Wednesday, April 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $118.17.

Abbott Laboratories Stock Up 1.0%

Shares of ABT opened at $109.70 on Wednesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a market capitalization of $189.82 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 2.10 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The business’s 50 day simple moving average is $96.38 and its 200-day simple moving average is $99.71.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period last year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.